The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study

Abstract

Minocycline has immunomodulatory and neuroprotective activities in vitro and in an animal model of multiple sclerosis (MS). We have previously reported that minocycline decreased gadolinium-enhancing activity over six months in a small trial of patients with active relapsing-remitting MS (RRMS). Here we report the impact of oral minocycline on clinical and magnetic resonance imaging (MRI) outcomes and serum immune molecules in this cohort over 24 months of open-label minocycline treatment. Despite a moderately high pretreatment annualized relapse rate (1.3/year pre-enrolment; 1.2/year during a three-month baseline period) prior to treatment, no relapses occurred between months 6 and 24. Also, despite very active MRI activity pretreatment (19/40 scans had gadolinium-enhancing activity during a three-month run-in), the only patient with gadolinium-enhancing lesions on MRI at 12 and 24 months was on half-dose minocycline. Levels of the p40 subunit of interleukin (IL)-12, which at high levels might antagonize the proinflammatory IL-12 receptor, were elevated over 18 months of treatment, as were levels of soluble vascular cell adhesion molecule-1. The activity of matrix metalloproteinase-9 was decreased by treatment. Thus, clinical and MRI outcomes are supported by systemic immunological changes and call for further investigation of minocycline in MS. Multiple Sclerosis 2007; 13: 517-526. http://msj.sagepub.com

Keywords

adhesion molecule interleukin-12 MMP multiple sclerosis neuroimmunology therapy

Get full access to this article

View all access options for this article.

References

Carney S. , Butcher RA , Dawborn JK , Pattison G. Minocycline excretion and distribution in relation to renal flunction in man . Clin Exp Pharmacol Physiol 1974; 1: 299-308 .

Macdonald H. , Kelly RG , Allen ES , Noble JF , Kanegis LA Pharmacokinetic studies on minocycline in man . Clin Pharmacol Ther 1973; 14: 852-61 .

Yong VW , Wells J. , Giuliani F. , Casha S. , Power C. , Metz LM The promise ofl minocycline in neurology . Lancet Neurol 2004; 3: 744-51 .

Brundula V. , Rewcastle NB , Metz LM , Bernard CC , Yong VW Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy flor multiple sclerosis . Brain 2002; 125: 1297-308 .

Nessler S. , Dodel R. , Bittner A. , Reuss S. , Du Y. , Hemmer B. et al. Eflflect ofl minocycline in experimental autoimmune encephalomyelitis . Ann Neurol 2002; 52: 689-90 .

Popovic N. , Schubart A. , Goetz BD , Zhang SC , Linington C. , Duncan ID Inhibition ofl autoimmune encephalomyelitis by a tetracycline . Ann Neurol 2002; 51: 215-23 .

Kloppenburg M. , Brinkman BM , de Rooij-Dijk HH , Miltenburg AM , Daha MR , Breedveld FC et al. The tetracycline derivative minocycline diflflerentially aflflects cytokine production by monocytes and T lymphocytes . Antimicrob Agents Chemother 1996; 40: 934-40 .

Metz LM , Zhang Y. , Yeung M. , Patry DG , Bell RB , Stoian CA et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis . Ann Neurol 2004; 55: 756 .

Mitchell JR , Karlik SJ , Lee DH , Fenser A. Computer-assisted identification and quantification ofl multiple sclerosis lesions in MR imaging volumes in the brain . J Magn Reson Imaging 1994; 4: 197-208 .

10.

Mitchell JR , Karlik SJ , Lee DH , Eliasziw M. , Rice GP , Fenster A. The variability ofl manual and computer assisted quantification ofl multiple sclerosis lesion volumes . Med Phys 1996; 23: 85-97 .

11.

Bickett D. , Green MD , Berman J. , Dezube M. , Howe AS , Brown PJ et al. A high throughput fluorogenic substrate flor interstitial collagenase (MMP-1) and gelatinase (MMP-9) . Anal Biochem 1993; 212: 58-64 .

12.

Hohlfeld R. , Meinl E. , Weber F. , Zipp F. , Schmidt S. , Sotgiu S. et al. The role ofl autoimmune T lymphocytes in the pathogenesis ofl multiple sclerosis . Neurology 1995; 45: S33-38 .

13.

Hafler DA Multiple sclerosis . J Clin Invest 2004; 113: 788-94 .

14.

Bette M. , Jin SC , Germann T. , Schafer MK , Weihe E. , Rude E. et al. Diflflerential expression ofl mRNA encoding interleukin-12 p35 and p40 subunits in situ . Eur J Immunol 1994 ; 24: 2435-40 .

15.

Mattner F. , Fischer S. , Guckes S. , Jin S. , Kaulen H. , Schmitt E. et al. The interleukin-12 subunit p40 specifically inhibits eflflects ofl the interleukin-12 heterodimer . Eur J Immunol 1993; 23: 2202-208 .

16.

Holscher C. The power ofl combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in inflectious diseases . Med Microbiol Immunol ( Berl ) 2004; 193: 1-17 .

17.

Ling P. , Gately MK , Gubler U. , Stern AS , Lin P. , Hollfelder K. et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity . J Immunol 1995; 154: 116-27 .

18.

Yoshimoto T. , Wang CR , Yoneto T. , Waki S. , Sunaga S. , Komagata Y. et al. Reduced T helper 1 responses in IL-12 p40 transgenic mice . J Immunol 1998; 160: 588-94 .

19.

Costa GL , Sandora MR , Nakajima A. , Nguyen EV , Taylor-Edwards C. , Slavin AJ et al. Adoptive immunotherapy ofl experimental autoimmune encephalomyelitis via T cell delivery ofl the IL-12 p40 subunit . J Immunol 2001; 167: 2379-87 .

20.

Bahner D. , Klucke C. , Kitze B. , Elitok E. , Bogumil T. , Dressel A. et al. Interfleron-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients . Neurosci Lett 2002; 326: 125-28 .

21.

Kasper L. Saflety, pharmacokinetic and biological response profile ofl an IL-12p40 antagonist in patients with multiple sclerosis: a phase I clinical trial . Neurol Suppl 2005; 64: a394 .

22.

Stallmach A. , Marth T. , Weiss B. , Wittig BM , Hombach A. , Schmidt C. et al. An interleukin 12 p40-IgG2b flusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo . Gut 2004; 53: 339-45 .

23.

Lee SJ , Benveniste EN Adhesion molecule expression and regulation on cells ofl the central nervous system . J Neuroimmunol 1999; 98: 77-88 .

24.

Calabresi PA , Tranquill LR , Dambrosia JM , Stone LA , Maloni H. , Bash CN et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interfleron beta-1b . Ann Neurol 1997; 41: 669-74 .

25.

Calabresi PA , Pelfrey CM , Tranquill LR , Maloni H. , McFarland HF VLA-4 expression on peripheral blood lymphocytes is downregulated aflter treatment ofl multiple sclerosis with interfleron beta . Neurology 1997; 49: 1111-16 .

26.

Trojano M. , Avolio C. , Ruggieri M. , De Robertis F. , Giuliani F. , Paolicelli D. et al. Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid ofl demyelinating diseases ofl the central and peripheral nervous system . Mult Scler 1998; 4: 39-44 .

27.

Yong VW , Power C. , Forsyth P. , Edwards DR Metalloproteinases in biology and pathology ofl the nervous system . Nat Rev Neurosci 2001; 2: 502-11 .

28.

Leppert D. , Waubant E. , Burk MR , Oksenberg JR , Hauser SL Interfleron beta-1b inhibits gelatinase secretion and in vitro migration ofl human T cells: a possible mechanism flor treatment eflficacy in multiple sclerosis . Ann Neurol 1996; 40: 846-52 .

29.

Stüve O. , Dooley NP , Uhm JH , Antel JP , Francis GS , Williams G. et al. Interfleron beta-1b decreases the migration ofl T lymphocytes in vitro: eflflects on matrix metalloproteinase-9 . Ann Neurol 1996; 40: 853-63 .

30.

Galboiz Y. , Shapiro S. , Lahat N. , Rawashdeh H. , Miller A. Matrix metalloproteinases and their tissue inhibitors as markers ofl disease subtype and response to interfleron-beta therapy in relapsing and secondary-progressive multiple sclerosis patients . Ann Neurol 2001 ; 50: 443-51 .

31.

Waubant E. , Goodkin D. , Bostrom A. , Bacchetti P. , Hietpas J. , Lindberg R. et al. IFNbeta lowers MMP-9/ TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS . Neurology 2003 ; 60: 52-57 .

32.

Ryan ME , Usman A. , Ramamurthy NS , Golub LM , Greenwald RA Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity . Curr Med Chem 2001; 8: 305-16 .

33.

Sena A. , Pedrosa R. , Graca Morais M. Therapeutic potential ofl lovastatin in multiple sclerosis . J Neurol 2003; 250: 754-55 .

34.

Vollmer T. , Key L. , Durkalski V. , Tyor W. , Corboy J. , Markovic-Plese S. et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis . Lancet 2004; 363: 1607-608 .